Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology
Disease Category: Prostate Disorders
Location: United States, CA

Clinical Trial Details

Overview

Research Study Summary

Enlarged Prostate Study

Purpose

A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)

Patient Inclusion Criteria:

  • Men 45+
  • PSA > 1.4 and < 10ng/mL
  • If hyperlipidemic, on stable statin treatment for at least two months

Patient Exclusion Criteria:

  • Proscar or Avodart within 6 months
  • Alpha blockers, herbal preparations, overactive bladder treatment within 1 month
  • E.D. treatment within 1 month
  • Testosterone replacement therapy within 1 month
  • Prior surgical or other invasive prostate procedures
  • Active cardiovascular disease (recent MI, unstable angina, stroke, TIA within 6 months)
  • Prostate, breast, or other cancer
  • Deep vein thrombosis

To Learn more
Phase

2

Gender

Male

Age

45 and up

Overall Status

Recruiting

Duration

24 Weeks

Facility Type

N/A

Contact

West Coast Clinical Research
5525 Etiwanda Ave., Suite 202
Tarzana, CA 91356
Phone: 818-776-0820, Ext. 101
Fax: 818-776-1269

View Map

Research Center Information: West Coast Clinical Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 164504

Date Last Changed: July 24, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.